The four major primary- and secondary-prevention patient
groups who should
be treated with statins were identified on the basis of
randomized, controlled clinical trials showing that the benefit of treatment
outweighed the risk of adverse events. The four treatment groups include:
·
Individuals
with clinical
atherosclerotic cardiovascular disease.
·
Individuals
with LDL-cholesterol
levels >190 mg/dL,
such as those with familial
hypercholesterolemia.
·
Individuals
with diabetes aged 40 to 75 years
old with LDL-cholesterol levels between 70 and 189 mg/dL and without evidence of atherosclerotic cardiovascular disease.
·
Individuals without evidence of cardiovascular disease or diabetes but who have LDL-cholesterol
levels between 70 and 189 mg/dL
and a 10-year
risk of atherosclerotic cardiovascular disease>7.5%.
